首页> 外文期刊>Circulation journal >Clinical protocol for angiogenesis by intramyocardial injection of autologous bone marrow mononuclear cells in patients with severe coronary artery disease: TACT-NAGOYA-HEART.
【24h】

Clinical protocol for angiogenesis by intramyocardial injection of autologous bone marrow mononuclear cells in patients with severe coronary artery disease: TACT-NAGOYA-HEART.

机译:在严重冠状动脉疾病患者中,通过心肌内注射自体骨髓单个核细胞进行血管生成的临床方案:TACT-NAGOYA-HEART。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Despite recent improvements in the treatments of coronary artery disease (CAD), there are a considerable number of patients who can not receive complete revascularization because of severe or total arterial occlusion. Intramyocardial injection of autologous bone marrow mononuclear cells (ABMMCs) has been shown to induce neovascularization of ischemic myocardium. METHODS AND RESULTS: The study will investigate the safety and feasibility of intramyocardial injections of ABMMCs and test the hypothesis that this treatment would promote neovascularization and improve left ventricular (LV) global and/or regional function in patients with severe CAD who have no other option. ABMMCs (approximately 10(6) cells) will be injected into the area of ischemic myocardium where the coronary artery is not graftable, in combination with bypass surgery to the other coronary branches. Myocardial perfusion and LV global and regional function will be evaluated, based on the micromanometer-tipped catheter method, single-photon emission tomography, and myocardial enhanced and color tissue Doppler echocardiography at baseline and during 12 month follow-up. CONCLUSIONS: This project will demonstrate that intramyocardial injection of ABMMCs with or without coronary artery bypass surgery could be a safe and effective method for therapeutic neovascularization, resulting in an improvement of cardiac function in patients with severe CAD.
机译:背景:尽管最近对冠状动脉疾病(CAD)的治疗有所改进,但仍有相当多的患者由于严重或完全动脉阻塞而无法进行完全的血运重建。心肌内注射自体骨髓单个核细胞(ABMMCs)已显示可诱导缺血性心肌的新血管形成。方法和结果:该研究将调查心肌内注射ABMMCs的安全性和可行性,并检验以下假设:该治疗方法将促进没有其他选择的严重CAD患者可以促进新血管形成并改善左心室(LV)的整体和/或局部功能。将ABMMC(大约10(6)个细胞)注射到缺血性心肌的冠状动脉不可移植的区域,并与其他冠状动脉分支搭桥手术相结合。在基线和12个月的随访期间,将基于微压力计导管方法,单光子发射断层扫描以及心肌增强和彩色组织多普勒超声心动图,评估心肌灌注以及LV的整体和区域功能。结论:该项目将证明在有或没有冠状动脉搭桥手术的情况下,心肌内注射ABMMCs可能是一种安全有效的新血管形成治疗方法,可改善重度CAD患者的心脏功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号